Concepedia

Publication | Open Access

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

DOIFull Paper Access

244

Citations

30

References

2015

Year

Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith C. McCaffrey, Kate Newbold, Roger Allison, Renato Martins,
Clinical Cancer Research

Abstract

Lenvatinib had a high ORR, high DCR, and a short TTR in patients with documented progressive MTC. Toxicities were managed with dose modifications and medications.

References

YearCitations

Page 1